Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PKBO NASDAQ:PTIX NASDAQ:TNFA NASDAQ:WINT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePKBOPeak Bio$0.02$0.05$0.00▼$0.26$520K1.758,940 shs66,140 shsPTIXAtrinsic$3.42-3.1%$3.91$2.35▼$15.54$2.01M0.34582,035 shs121,951 shsTNFATNF Pharmaceuticals$0.09-7.6%$0.15$0.08▼$2.16$1.24M1.982.57 million shs31.20 million shsWINTWindtree Therapeutics$1.19+13.3%$0.72$0.36▼$737.44$4.36M0.73.21 million shs19.25 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePKBOPeak Bio0.00%0.00%0.00%0.00%+134.38%PTIXAtrinsic-3.12%-7.32%-0.58%+1.83%-65.20%TNFATNF Pharmaceuticals-7.60%-19.72%-37.41%-52.24%+8,749,900.00%WINTWindtree Therapeutics+13.33%+63.01%+116.36%+4.39%-99.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPKBOPeak BioN/AN/AN/AN/AN/AN/AN/AN/APTIXAtrinsic0.1131 of 5 stars0.02.00.00.00.01.70.0TNFATNF PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AWINTWindtree Therapeutics2.9956 of 5 stars3.05.00.00.03.00.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePKBOPeak Bio 0.00N/AN/AN/APTIXAtrinsic 0.00N/AN/AN/ATNFATNF Pharmaceuticals 0.00N/AN/AN/AWINTWindtree Therapeutics 2.00Hold$350.0029,311.76% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPKBOPeak Bio$370K1.41N/AN/A($0.90) per share-0.03PTIXAtrinsicN/AN/AN/AN/A$1.96 per shareN/ATNFATNF PharmaceuticalsN/AN/AN/AN/A$2.87 per shareN/AWINTWindtree TherapeuticsN/AN/AN/AN/A$38.99 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePKBOPeak Bio-$12.83M-$0.16N/A∞N/AN/AN/A-179.31%N/APTIXAtrinsic-$5.53M-$13.11N/A∞N/AN/A-860.52%-354.19%8/12/2025 (Estimated)TNFATNF Pharmaceuticals-$23.36M-$6.67N/A∞N/AN/A-97.38%-37.37%8/18/2025 (Estimated)WINTWindtree Therapeutics-$1.79M-$823.47N/AN/AN/AN/A-227.93%-56.46%8/18/2025 (Estimated)Latest PKBO, PTIX, WINT, and TNFA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025TNFATNF PharmaceuticalsN/A-$0.36N/A-$0.36N/AN/A5/15/2025Q1 2025WINTWindtree Therapeutics-$39.00-$4.63+$34.37-$4.63$2.20 millionN/A5/13/2025Q1 2025PTIXAtrinsicN/A-$2.75N/A-$2.75N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPKBOPeak BioN/AN/AN/AN/AN/APTIXAtrinsicN/AN/AN/AN/AN/ATNFATNF PharmaceuticalsN/AN/AN/AN/AN/AWINTWindtree TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPKBOPeak BioN/A0.070.06PTIXAtrinsicN/A0.860.86TNFATNF PharmaceuticalsN/A1.371.37WINTWindtree TherapeuticsN/A0.250.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPKBOPeak BioN/APTIXAtrinsic7.97%TNFATNF Pharmaceuticals9.64%WINTWindtree Therapeutics29.33%Insider OwnershipCompanyInsider OwnershipPKBOPeak Bio19.90%PTIXAtrinsic35.00%TNFATNF Pharmaceuticals0.45%WINTWindtree Therapeutics0.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePKBOPeak Bio323.13 million18.52 millionNot OptionablePTIXAtrinsic2589,000383,000Not OptionableTNFATNF Pharmaceuticals614.18 million14.12 millionN/AWINTWindtree Therapeutics303.66 million3.65 millionNot OptionablePKBO, PTIX, WINT, and TNFA HeadlinesRecent News About These CompaniesWindtree Shares Soar More Than 100% on BNB Treasury Plans4 hours ago | msn.comNasdaq Biotech Firm Windtree to Raise $200M for First-Ever BNB Crypto Treasury0July 18 at 9:17 AM | thecurrencyanalytics.comTBiotech Company Windtree to Raise Up to $200M for BNB TreasuryJuly 17 at 5:19 AM | coindesk.comBNB gains 3% following Windtree's plan to launch BNB treasury, H1 reportJuly 16 at 12:18 AM | fxstreet.comWindtree Becomes First NASDAQ Firm to Add BNB to Its Balance SheetJuly 16 at 7:17 PM | blockonomi.comWindtree to raise $200M to launch a BNB treasury strategyJuly 16 at 7:17 PM | msn.comWindtree Therapeutics, Inc. Announces $60 Million Securities Purchase Agreement to Launch BNB Crypto Treasury StrategyJuly 16 at 9:36 AM | quiverquant.comQWindtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On SubscriptionsJuly 16 at 9:22 AM | globenewswire.comWindtree Therapeutics Announces U.S. Patent Grant for Istaroxime in Acute Heart Failure Treatment - NasdaqJuly 4, 2025 | nasdaq.comWindtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart FailureJuly 2, 2025 | globenewswire.comWindtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim AnalysisJune 30, 2025 | finance.yahoo.comWindtree Therapeutics Signs Agreement to Cut PHEXXI Manufacturing Costs by Over 50% Through Partnership with Chinese ManufacturerJune 26, 2025 | quiverquant.comQWindtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive GelJune 26, 2025 | globenewswire.comWindtree Therapeutics Announces Promising Phase 2 Study Results for IstaroximeJune 17, 2025 | msn.comWindtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B StudyJune 16, 2025 | manilatimes.netMWindtree Therapeutics Receives $7 Million Offer for Preclinical Oncology PlatformJune 14, 2025 | msn.comWindtree Therapeutics: Windtree Receives Offer for Its Preclinical Oncology Drug CandidateJune 13, 2025 | finanznachrichten.deWindtree Receives Offer for Its Preclinical Oncology Drug CandidateJune 11, 2025 | tmcnet.comWindtree Therapeutics, Inc. Secures $7 Million Up Front for Preclinical Oncology Drug Candidate, Potentially Worth $130 Million in Milestones and $1.5 Billion in RoyaltiesJune 11, 2025 | quiverquant.comQWorking to clean up its finances, Windtree Therapeutics gets into the garbage businessJune 10, 2025 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePKBO, PTIX, WINT, and TNFA Company DescriptionsPeak Bio NASDAQ:PKBOPeak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.Atrinsic NASDAQ:PTIX$3.42 -0.11 (-3.12%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$3.42 0.00 (0.00%) As of 07/18/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.TNF Pharmaceuticals NASDAQ:TNFA$0.09 -0.01 (-7.60%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.12 +0.03 (+32.57%) As of 07/18/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.Windtree Therapeutics NASDAQ:WINT$1.19 +0.14 (+13.33%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.19 +0.00 (+0.08%) As of 07/18/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
